ARVN
Company Description
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer; and ARV-766 an investigational orally bioavailable PROTAC protein degrader for the treatment of men with mCRPC. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Arvinas, Inc. was founded in 2013 and is based in New Haven, Connecticut.
Track Record
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 262.60M | 263.40M | 78.50M | 131.40M | 53.60M | 25.90M | 42.98M | 14.32M | 7.58M | 6.67M |
| Net Income | (80.80M) | (198.90M) | (367.30M) | (282.50M) | (191.00M) | (119.30M) | (70.29M) | (41.48M) | (24.05M) | (14.35M) |
| EPS | -1.28 | -2.77 | -6.62 | -5.31 | -3.82 | -3.02 | -1.89 | -1.31 | -1.38 | -7.56 |
| Free Cash Flow | (275.70M) | (261.10M) | (350.70M) | (280.30M) | 554.70M | (96.20M) | (46.87M) | (18.95M) | 4.10M | (19.71M) |
| FCF / Share | -4.25 | -3.63 | -6.32 | -5.27 | 11.09 | -2.43 | -1.42 | -0.60 | 0.20 | -10.39 |
| Operating CF | (273.80M) | (259.30M) | (347.80M) | (273.50M) | 559.40M | (89.76M) | (40.63M) | (16.12M) | 5.11M | (19.40M) |
| Total Assets | 717.90M | 1.09B | 1.30B | 1.27B | 1.58B | 717.40M | 301.64M | 199.28M | 66.85M | 37.94M |
| Total Debt | 8.90M | 9.70M | 3.20M | 5.50M | 5.00M | 4.10M | 4.39M | 2.15M | 310,387 | 453,787 |
| Cash & Equiv | 142.90M | 100.50M | 311.70M | 81.30M | 108.30M | 588.40M | 9.21M | 3.19M | 30.91M | 5.09M |
| Book Value | 433.80M | 561.70M | 660.00M | 564.90M | 781.70M | 642.20M | 226.69M | 136.67M | 245,870 | 24.03M |
| Return on Equity | -0.19 | -0.35 | -0.56 | -0.50 | -0.24 | -0.19 | -0.31 | -0.30 | -97.81 | -0.60 |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 15.60M | 9.50M | 41.90M | 22.40M | 188.80M | 59.20M | 102.40M | 76.50M | 25.30M | (43.10M) | 34.60M | 54.50M |
| Net Income | (57.60M) | (67.40M) | (35.10M) | (61.20M) | 82.90M | (45.10M) | (49.20M) | (35.20M) | (69.40M) | (154.80M) | (64.00M) | (66.60M) |
| EPS | -0.90 | -1.04 | -0.48 | -0.84 | 1.14 | -0.63 | -0.68 | -0.49 | -0.97 | -2.53 | -1.18 | -1.25 |
| Free Cash Flow | (70.50M) | (30.60M) | (59.20M) | (96.60M) | (89.30M) | (84.40M) | (128.70M) | 49.60M | (97.60M) | (83.20M) | (85.90M) | (89.30M) |
| FCF / Share | -1.10 | -0.47 | -0.81 | -1.33 | -1.23 | -1.17 | -1.79 | 0.69 | -1.36 | -1.36 | -1.59 | -1.67 |
| Operating CF | (69.20M) | (30.40M) | (59.10M) | (95.40M) | (88.90M) | (84.10M) | (128.00M) | 50.30M | (97.50M) | (83.10M) | (84.80M) | (88.70M) |
| Total Assets | 647.50M | 717.90M | 844.30M | 909.30M | 1.00B | 1.09B | 1.17B | 1.28B | 1.21B | 1.30B | 1.06B | 1.08B |
| Total Debt | 8.60M | 8.90M | 9.50M | 9.90M | 10.50M | 9.70M | 1.50M | 2.10M | 2.60M | 3.20M | 4.00M | 4.50M |
| Cash & Equiv | 87.30M | 142.90M | 101.50M | 114.90M | 81.00M | 100.50M | 85.20M | 154.80M | 88.00M | 311.70M | 113.70M | 90.60M |
| Book Value | 386.80M | 433.80M | 564.40M | 609.30M | 660.10M | 561.70M | 586.00M | 600.10M | 609.70M | 660.00M | 457.20M | 463.60M |
| Return on Equity | -0.15 | -0.16 | -0.06 | -0.10 | 0.13 | -0.08 | -0.08 | -0.06 | -0.11 | -0.23 | -0.14 | -0.14 |
